These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9522542)

  • 1. [Noncompliance--a typical problem in psychiatric patients. Individual, social and illness-specific factors].
    Hartung HD
    Fortschr Med; 1998 Jan; 116(3):28-30. PubMed ID: 9522542
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview of partial compliance.
    Marder SR
    J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Which factors modify drug-compliance?].
    Albus M; Burkes S; Scherer J
    Psychiatr Prax; 1995 Nov; 22(6):228-30. PubMed ID: 8570752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 5. Ideal and reality of neuroleptic relapse prevention.
    Kissling W
    Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 7. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors influencing compliance in schizophrenia patients.
    Fleischhacker WW; Oehl MA; Hummer M
    J Clin Psychiatry; 2003; 64 Suppl 16():10-3. PubMed ID: 14680413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract]   [Full Text] [Related]  

  • 10. [Early detection of schizophrenic psychoses].
    Lauber C; Rössler W
    Praxis (Bern 1994); 2001 May; 90(22):987-92. PubMed ID: 11450187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Better prognosis due to new treatment approaches. Therapy of schizophrenia in 2002].
    Janssen B; Gaebel W
    MMW Fortschr Med; 2002 May; Suppl 2():72-6, 78. PubMed ID: 12070858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia.
    Kamali M; Kelly L; Gervin M; Browne S; Larkin C; O'Callaghan E
    Psychiatr Serv; 2001 Feb; 52(2):161-3, 166. PubMed ID: 11157110
    [No Abstract]   [Full Text] [Related]  

  • 14. Choice of maintenance medication for schizophrenia.
    Davis JM; Chen N
    J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication nonadherence may lead to hospitalization.
    J Psychosoc Nurs Ment Health Serv; 2003 Aug; 41(8):10. PubMed ID: 13677006
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 19. Preliminary trial of clonidine treatment in two patients suffering from chronic schizophrenia.
    Elizur A; Levy A; Lahav M; Blum I
    Commun Psychopharmacol; 1980; 4(6):507-17. PubMed ID: 6117398
    [No Abstract]   [Full Text] [Related]  

  • 20. [Presentation of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine].
    Stengler-Wenzke K
    Psychiatr Prax; 1999 May; 26(3):145-6. PubMed ID: 10412713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.